Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Anti-Fibrinolytic Drugs Market: By Form: Oral, Injectable; By Type: Amicor, Aminocaproic acid, Aprotinin, Lysteda, RiaSTAP, Fibrinogen, Tranexamic Acid, Trasylol, Others; By Indication; By End Use; Regional Analysis; Historical Market and Forecast (2015-2025); Competitive Landscape; Industry Events and Developments

Global Anti-Fibrinolytic Drugs Market Outlook

The global anti-fibrinolytic drugs market witnessed a healthy growth in the historical period of 2015-2019 aided by the rising healthcare sector in the emerging regions. The market is further expected to grow at a CAGR of 5% in the forecast period of 2020-2025.

 

North America to be a Significant Anti-Fibrinolytic Drugs Market

North America has been a significant market for anti-fibrinolytic drugs in the past years and is expected to continue the trend. This dominance of the region can be attributed to the rising numbers of severe road accidents and trauma. A significant proportion of the deaths in North America are reported to be caused by trauma. The rising incidences of platelet dysfunctions, Von Willebrand disease, haemophilia A and B, which require anti-fibrinolytic drugs to inhibit fibrinolysis, are expected to contribute to the growth of the anti-fibrinolytic drugs industry in North America. Europe, the Asia Pacific, and Latin America are the other significant markets for the drugs, apart from North America. The growing investments in healthcare R&D are expected to augment the anti-fibrinolytic drugs industry growth globally in the forecast period.

 

Anti-Fibrinolytic Drugs: Industry Definition and Segmentation

Fibrinolysis is a natural physiological process that prevents blood clotting. It is carried out by converting plasminogen to plasmin. It can cause persistent bleeding and trauma, which might ultimately lead to death. Anti-fibrinolytic drugs like aminocaproic acid and tranexamic acid are lysine-like agents that prevent plasmin (fibrinolytic enzyme) formation by hindering the binding sites of the enzyme at lysin-rich areas, thus, inhibiting fibrinolysis. These drugs are used in the treatment of various coagulation disorders and medical surgeries.

By form, the market can be segmented into:

  • Oral 
  • Injectable

Based on type, the market can be classified into amicor, aminocaproic acid, aprotinin, lysteda, riaSTAP, fibrinogen, tranexamic acid, and trasylol, among others.
 
Based on indication, the market is segmented into:

  • Gynaecology
  • Hereditary Angioedema
  • Fibrinolytic Response Testing
  • Surgeries
  • Others

Based on end-use, the market can be categorised into:

  • Hospitals
  • Ambulatory Surgery Centres
  • Health Care Speciality Processes
  • Clinics

The EMR report looks into the regional markets of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

 

Rise in Road Accidents to Drive the Anti-Fibrinolytic Drugs Market Growth

The market is being driven by a significant rise in road accidents, which cause severe bleeding. Trauma is observed to be one of the significant mortality causes across the world, hence, increasing the demand for anti-fibrinolytic drugs. Further, the usage of the drugs in oral bleeding treatments is bolstering the market growth further. The rising adoption of these drugs for the treatment of menorrhagia, i.e., heavy menstrual flow, is expected to bolster the anti-fibrinolytic drugs industry in the coming years. The increasing investments in the R&D of hemophilia products are also predicted to influence the demand for the drugs in the forecast period.
 

Key Industry Players in the Global Anti-Fibrinolytic Drugs Market

The report presents a detailed analysis of the following key players in the global anti-fibrinolytic drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Pfizer Inc.
  • Sanofi SA
  • Akorn, Inc
  • Cadila Healthcare Ltd.
  • Takeda Pharmaceutical Company Limited
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Anti-Fibrinolytic Drugs Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Anti-Fibrinolytic Drugs Historical Market (2015-2019) 
    8.3    Global Anti-Fibrinolytic Drugs Market Forecast (2020-2025)
    8.4    Global Anti-Fibrinolytic Drugs Market by Form
        8.4.1    Oral
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2015-2019)
            8.4.1.3    Forecast Trend (2020-2025)
        8.4.2    Injectable
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2015-2019)
            8.4.2.3    Forecast Trend (2020-2025)
    8.5    Global Anti-Fibrinolytic Drugs Market by Type
        8.5.1    Amicor
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2015-2019)
            8.5.1.3    Forecast Trend (2020-2025)
        8.5.2    Aminocaproic acid
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2015-2019)
            8.5.2.3    Forecast Trend (2020-2025)
        8.5.3    Aprotinin
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2015-2019)
            8.5.3.3    Forecast Trend (2020-2025)
        8.5.4    Lysteda
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2015-2019)
            8.5.4.3    Forecast Trend (2020-2025)
        8.5.5    RiaSTAP
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2015-2019)
            8.5.5.3    Forecast Trend (2020-2025)
        8.5.6    Fibrinogen
            8.5.6.1    Market Share
            8.5.6.2    Historical Trend (2015-2019)
            8.5.6.3    Forecast Trend (2020-2025)
        8.5.7    Tranexamic Acid
            8.5.7.1    Market Share
            8.5.7.2    Historical Trend (2015-2019)
            8.5.7.3    Forecast Trend (2020-2025)
        8.5.8    Trasylol
            8.5.8.1    Market Share
            8.5.8.2    Historical Trend (2015-2019)
            8.5.8.3    Forecast Trend (2020-2025)
        8.5.9    Others
    8.6    Global Anti-Fibrinolytic Drugs Market by Indication
        8.6.1    Gynaecology
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2015-2019)
            8.6.1.3    Forecast Trend (2020-2025)
        8.6.2    Hereditary Angioedema
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2015-2019)
            8.6.2.3    Forecast Trend (2020-2025)
        8.6.3    Fibrinolytic Response Testing
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2015-2019)
            8.6.3.3    Forecast Trend (2020-2025)
        8.6.4    Surgeries
            8.6.4.1    Market Share
            8.6.4.2    Historical Trend (2015-2019)
            8.6.4.3    Forecast Trend (2020-2025)
        8.6.5    Others
    8.7    Global Anti-Fibrinolytic Drugs Market by End Use
        8.7.1    Hospitals
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2015-2019)
            8.7.1.3    Forecast Trend (2020-2025)
        8.7.2    Ambulatory Surgery Centres
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2015-2019)
            8.7.2.3    Forecast Trend (2020-2025)
        8.7.3    Health Care Specialty Processes.
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2015-2019)
            8.7.3.3    Forecast Trend (2020-2025)
        8.7.4    Clinics
            8.7.4.1    Market Share
            8.7.4.2    Historical Trend (2015-2019)
            8.7.4.3    Forecast Trend (2020-2025)
    8.8    Global Anti-Fibrinolytic Drugs Market by Region
        8.8.1    Market Share
            8.8.1.1    North America
            8.8.1.2    Europe
            8.8.1.3    Asia Pacific
            8.8.1.4    Latin America
            8.8.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2015-2019)
        9.1.2    Forecast Trend (2020-2025)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2015-2019)
        9.2.2    Forecast Trend (2020-2025)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2015-2019)
        9.3.2    Forecast Trend (2020-2025)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2015-2019)
        9.4.2    Forecast Trend (2020-2025)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2015-2019)
        9.5.2    Forecast Trend (2020-2025)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Pfizer Inc.
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Sanofi SA
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Akorn, Inc.
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Cadila Healthcare Ltd.
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Takeda Pharmaceutical Company Limited
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Others
13    Industry Events and Developments

 

List of Figures and Tables

1.    Global Anti-Fibrinolytic Drugs Market: Key Industry Highlights, 2015 and 2025
2.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Form (USD Billion), 2015-2019
3.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Form (USD Billion), 2020-2025
4.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Type (USD Billion), 2015-2019
5.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Type (USD Billion), 2020-2025
6.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Indication (USD Billion), 2015-2019
7.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Indication (USD Billion), 2020-2025
8.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by End Use (USD Billion), 2015-2019
9.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by End Use (USD Billion), 2020-2025
10.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Region (USD Billion), 2015-2019
11.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Region (USD Billion), 2020-2025
12.    North America Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2015-2019
13.    North America Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2020-2025
14.    Europe Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2015-2019
15.    Europe Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2020-2025
16.    Asia Pacific Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2015-2019
17.    Asia Pacific Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2020-2025
18.    Latin America Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2015-2019
19.    Latin America Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2020-2025
20.    Middle East and Africa Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2015-2019
21.    Middle East and Africa Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2020-2025
22.    Global Anti-Fibrinolytic Drugs Market Structure

Key Questions Answered in the Report

The market is projected to grow at a CAGR of 5% between 2020 and 2025.

The major market drivers include the rising frequency of road accidents, increasing usage of the product in oral bleeding treatments, and the rising R&D investments in hemophilia products.

The key trends steering the market include the growing adoption of the drugs in the treatment of menorrhagia.

The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

The major types of the drugs in the market are amicor, aminocaproic acid, aprotinin, lysteda, RiaSTAP, fibrinogen, tranexamic acid, and trasylol, among others.

Oral and injectable are the leading forms of the product in the industry.

The major indication segments within the market are gynaecology, hereditary angioedema, fibrinolytic response testing, and surgeries, among others.

The significant end use sectors within the market are hospitals, ambulatory centres, health care specialty processes, and clinics.

Pfizer Inc., Sanofi SA, Akorn, Inc, Cadila Healthcare Ltd., and Takeda Pharmaceutical Company Limited, among others, are the key industry players.

Analyst Review

The global anti-fibrinolytic drugs market is driven by the rising demand for the product in hemophilia treatments. Aided by the increasing investments in R&D, the market is expected to witness a healthy growth in the forecast period of 2020-2025, growing at a CAGR of 5%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. On the basis of form, the industry can be bifurcated into oral and injectable. Based on its types, the market can be segmented into amicor, aminocaproic acid, aprotinin, lysteda, riaSTAP, fibrinogen, tranexamic acid, and trasylol, among others. On the basis of indication, the market is divided into gynaecology, hereditary angioedema, fibrinolytic response testing, and surgeries, among others. By end use, the market is categorised into hospitals, ambulatory centres, health care specialty processes, and clinics. The major regional markets for the anti-fibrinolytic drugs are North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The key players in the above market include Pfizer Inc., Sanofi SA, Akorn, Inc, Cadila Healthcare Ltd., and Takeda Pharmaceutical Company, among others.

LimitedEMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 1099     $999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Single User License

$ 2999     $1999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Five User License

$ 3999     $2999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Corporate License

$ 4999     $3999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports

Global Trenbolone Enanthate Market Report and Forecast 2020-2025


Global Alprazolam Powder Market Report and Forecast 2020-2025


Global Legal Marijuana Market Report and Forecast 2020-2025




NEWSLETTER